Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Baudax Bio (NASDAQ:BXRX) announced that Gerri Henwood, President and CEO, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baudax Bio (NASDAQ:BXRX) announced that Gerri Henwood, President and CEO, will present at the H.C. Wainwright Annual Global Life Sciences Conference on May 25, 2022, at 1:30 p.m. Eastern Time in Miami, Florida. A webcast of the presentation will be available on the company's investors page and archived for 90 days. Baudax Bio focuses on innovative products for acute care, including its flagship product, ANJESO, the first intravenous COX-2 preferential NSAID for moderate to severe pain, along with a promising pipeline of neuromuscular blocking agents.
Details
News Market Reaction – BXRX
The recorded move for BXRX in the trading session of this news was -31.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright Annual Global Life Sciences Conference, taking place in Miami, Florida on Wednesday, May 25, 2022, at 1:30 p.m. Eastern Time.
A webcast of the presentation will be available on the “Events” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The webcast will be archived on the company’s website for 90 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.